CRISPR Therapeutics AG (CRSP) Free Cash Flow (2015 - 2026)

CRISPR Therapeutics AG has disclosed Free Cash Flow across 12 years of filings, most recently posting -$84.1 million for Q2 2026.

• In Q2 2026, Free Cash Flow rose 26.19% year-over-year to -$84.1 million; the TTM figure through Jun 2026 stood at -$371.3 million (down 14.05% YoY), while the FY2025 annual figure was -$345.9 million, down 139.11% from the prior year.
• Free Cash Flow came in at -$84.1 million for Q2 2026 at CRISPR Therapeutics AG, up from -$109.4 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $109.0 million in Q1 2024 to a low of -$151.6 million in Q2 2022.
• Average Free Cash Flow over 5 years is -$82.6 million, with a median of -$96.6 million recorded in 2023.
• The largest YoY upside for Free Cash Flow was 1799.49% in 2024 against a maximum downside of 155.23% in 2024.
• Over 5 years, Free Cash Flow stood at -$119.5 million in 2022, then grew by 19.0% to -$96.8 million in 2023, then jumped by 48.06% to -$50.3 million in 2024, then sank by 85.09% to -$93.1 million in 2025, then advanced by 9.59% to -$84.1 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$84.1 million in Q2 2026, -$109.4 million in Q1 2026, and -$93.1 million in Q4 2025.